ДАДЛИ Майкл Н. (US),БЕРКЛИ Нил (US),ГРИФФИТ Дэвид К. (US),ЛОУТИТ Джеффри С. (US),МОРГАН Элизабет И. (US),БОСТИАН Кейс А. (US),СЕТХИ Санджай (US)
申请号：
RU2012108962/15
公开号：
RU2012108962A
申请日:
2010.08.19
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A solution containing levofloxacin or ofloxacin in the form of an aerosol for use in reducing the frequency of acute attacks of a pulmonary disease selected from chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) in a population of people with this disease, where the frequency of attacks in this population is reduced to less than about 6 seizures per patient per year. 2. The aerosolized solution of claim 1, wherein the frequency of seizures in said population is reduced to less than about 3 seizures per patient per year. The aerosolized solution according to claim 1, wherein the frequency of seizures in said population is reduced to less than about 1.4 seizures per patient per year. The aerosolized solution according to claim 1, wherein the frequency of seizures in said population is reduced to less than about 1.2 seizures per patient per year. The aerosolized solution of claim 1, wherein the frequency of seizures in said population decreases to less than about 1.0 seizures per patient per year. The aerosolized solution of claim 1, wherein the frequency of seizures in said population is reduced to less than about 0.5 seizures per patient per year. The aerosolized solution of claim 1, further comprising a divalent or trivalent cation. The aerosol solution according to claim 1, not containing lactose. The aerosol solution according to claim 1, containing a concentration of a divalent or trivalent cation from about 50 mM to about 400 mM and a concentration of levofloxacin or ofloxacin from about 50 mg / ml to about 200 mg / ml. The aerosol solution according to claim 1, containing a concentration of a divalent or trivalent cation from about 100 mM to about 300 mM and a concentration of levofloxacin or ofloxacin1. Раствор, содержащий левофлоксацин или офлоксацин, в форме аэрозоля для применения в снижении частоты острых приступов легочного заболевания, выбранного из хронической обструктивной болезни легких (ХОБЛ) и хронического бронхита (ХБ), в
